Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia

Schizophrenia Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02248987
• Other study ID #: 3420130030
• Status: Completed
• Start date: May 2014
• Est. completion date: May 2016

Study information

• Verified date: April 2019
• Source: Seoul National University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate abnormal dopamine synthesis and connectivity according to the antipsychotic treatment response in schizophrenia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 55 Years

Eligibility

Inclusion Criteria:

• diagnosis of schizophrenia

• clinically stable state

Exclusion Criteria:

• history of previous head injury, epileptic disorder, other medical comorbidity

• substance abuse/dependence

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Other:
• patients treated with antipsychotics

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Striatal [18F]-DOPA uptake measured using positron emission tomographic 18F-dopa imaging.		within 2 weeks from enrollment
Secondary	resting state functional magnetic resonance imaging		within 2 weeks from enrollment
Secondary	diffusion tensor imaging		within 2 weeks from enrollment
Secondary	clinical measure including Positive and Negative Syndrome Scale		within 2 weeks from enrollment
Secondary	neurocognitive function test		within 2 weeks from enrollment